April 15th 2025
The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.
Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
View More
Southern Florida Psychiatry Conference
November 21-22, 2025
Register Now!
Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
View More
Optimizing Care for Patients With Tardive Dyskinesia
View More
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
View More
Initial studies-such as the stepped collaborative care intervention, Texas Medication Algorithm Project (TMAP), and German Algorithm Project (GAP) phase 2-predominantly investigated whether following an expert opinion–based clinical algorithm (irrespective of the content of the algorithm) led to a better outcome than treatment as usual did
Read More
Conflict of Interest in Psychiatry: How Much Disclosure Is Necessary?
November 1st 2006Just how “hot” is the topic of conflict of interest in psychiatry? The answer was brought home to me dramatically this past May at the APA meeting in Toronto. During the meeting, I had the opportunity to chair a symposium titled “Pharmaceutical Industry Influence in Psychiatry.” My copresenters and I showed up well ahead of time to meet and prepare introductions. As we gazed out at the empty seats, we joked that there would be at least 5 people in attendance since, after all, there were 5 presenters.
Read More
Treatment-Resistant Anxiety Disorders: Neurotrophic Perspectives
October 31st 2006Anxiety disorders are the most prevalent psychiatric disorders in the United States. Although effective treatments are available, such as the SSRIs and cognitive-behavioral therapy (CBT), it is estimated that in about 40% of patients, anxiety disorders are partially or completely resistant to first-line treatment.
Read More
Pathology and Management of Treatment Resistance in Bipolar Disorder
October 30th 2006The problem of treatment resistance in bipolar disorder begins with its definition. Characterizing the phases of bipolar disorder as manic, mixed, hypomanic, or depressed does not do justice to the reality for many persons with this disorder.
Read More
Anesthetic Trumps Treatment-Resistant Depression
October 1st 2006A small group of patients with treatment-resistant major depression achieved symptom relief within hours of receiving a single low-dose intravenous infusion of ketamine. The low-dose anesthetic apparently triumphed in these patients where other treatments including oral antidepressants, which can take 8 weeks or longer to "kick in" failed.
Read More
Cortisol and Seasonal Changes in Mood and Behavior
October 1st 2006The degree to which season changes affect mood, energy, sleep, appetite, food preference, or desire to socialize with others has been called "seasonality." Identification of a seasonal pattern can only be made if both the patient and physician actively look for it.
Read More
Children's and Parents' Attitudes About Participation in Treatment Research
October 1st 2006Since children are a vulnerable population, ethical issues in the conduct of medication studies involving them are extremely important. We recently reported the results of a study that examined youths' and parents' attitudes about, and experiences with, participation in psychopharmacology treatment research.
Read More
Addressing Psychiatric Comorbidities in Patients With Epilepsy
October 1st 2006In a presentation given at the midyear meeting of the American Epilepsy Society, Andres Kanner, MD cited studies from the literature showing that the rates of depression, anxiety, psychosis, and attention-deficit/hyperactivity disorder (ADHD) are significantly higher among persons with epilepsy than among the general population
Read More
Treating Adolescents With Major Depression and an Alcohol Use Disorder
October 1st 2006Alcohol is the drug of choice for adolescents, with cigarettes and marijuana being second and third. Contrary to widespread belief, alcohol dependence is most common in 18- to 20-year-olds, with progressively decreasing rates of alcohol dependence in older age groups.
Read More
Depression Management in Cancer Patients
October 1st 2006Depressive disorders and symptoms are common in cancer patients (up to 58% have depressive symptoms and up to 38% have major depression), worsen over the course of cancer treatment, persist long after cancer therapy, recur with the recurrence of cancer, and significantly impact quality of life.
Read More
Bipolar Disorder: Defining Remission and Selecting Treatment
October 1st 2006The longitudinal course of bipolar disorder (BD) is characterized by a low rate of recovery, a high rate of recurrence, and poor interepisodic functioning. There is a need to invoke a chronic disease management model (CDMM) when treating individuals with BD.
Read More
Alternative Brief Interventions for Mild Depression
October 1st 2006Depression has long been recognized as a primary concern for health care providers. Many approaches to treating depression have been developed, ranging from medications, to long-term psychotherapy, to shorter, more structured cognitive-behavioral treatments--all of which help some of the patients, some of the time, to some extent.
Read More
ADHD in Girls: Wide Range of Negative Sequelae
September 1st 2006Attention-deficit/hyperactivity disorder (ADHD) in girls may be more persistent than originally thought and may also be associated with a variety of behavioral and mental health consequences such as eating disorders, depression, and substance abuse.
Read More
Rebels Without a Cause? Adolescents and Their Antiheroes
Adolescents reject their parents’ icons and seek out and empower their own. Antiheroes seem deliberately provocative, assailing almost every social convention of the adult generation, and parents often fear they are leading youth astray.
Read More
Prenatal Antidepressant Use: Time for a Pregnant Pause?
September 1st 2006A young mother has just learned from her gynecologist that she is 2 months pregnant. She has had 7 major depressive episodes over the past 8 years, 3 of which were accompanied by serious suicide attempts. She is asking you if she should stop taking the antidepressant at this time. What do you advise?
Read More
10-Point Clock Test Screens for Cognitive Impairment in Clinic and Hospital Settings
August 25th 2006The obvious sometimes bears repeating: Sick people have trouble thinking. They may be suffering from a delirium, a dementia or a more subtle disturbance of cognition caused by fever, drugs, infection, inflammation, trauma, hypoxemia, metabolic derangement, hypotension, tumor, intracranial pathology, pain and so forth.
Read More
Fostering “Buy-In”: Step One in Bipolar Spectrum Treatment
August 1st 2006A look at how to use the spectrum concept to promote understanding and acceptance of bipolar II and soft bipolar diagnoses. In this article, you will find 5 tools for fostering what has been called “concordance” or, more simply, “buy-in.”
Read More
The Clinical Challenge of Comorbid Bipolar Disorder and Substance Use Disorder
August 1st 2006Bipolar disorder I and II have the highest association with substance use disorder, compared with any other major psychiatric disorder. Treatment requires an integrated approach that includes specific psychotherapy as well as the use of medication.
Read More